Background {#s1}
==========

Chorioamnionitis (CA) is an infection/inflammation of the placenta and fetal membranes; it complicates up to 5.2% of live births ([@B1]) with histological CA (HCA) being found in 23.6% to 28.7% of term births with spontaneous labor ([@B2], [@B3]). HCA has been linked to several common chronic diseases of childhood: cerebral palsy, developmental delay, asthma and allergic disorders ([@B4]--[@B13]). The exact mechanism of these associations is unclear. Exposure to perinatal inflammation may stimulate epigenetic changes that alter immune function and subsequently contribute to these pathologies.

Prior studies have shown an association between perinatal environment, including epigenetic changes, and disease later in life ([@B14], [@B15]). Epigenetic changes can occur through multiple mechanisms including histone modification, DNA methylation, and RNA interference. DNA methylation is an enzyme-mediated change to DNA in which a methyl group is added to cytosine at CpG sites, an important mechanism of transcriptional regulation ([@B16]). Increased methylation results in reduced transcription of adjacent genes while decreased methylation results in increased transcription of adjacent genes. HCA is known to be associated with epigenetic changes via DNA methylation of key developmental genes in preterm neonates ([@B17]). Additionally, DNA methylation has been shown to be altered in placentas and fetal membranes with HCA ([@B18]).

The effects of HCA on DNA methylation in full term neonates are not yet known and may be an important mechanism in increasing susceptibility to disease later in life. Our objective was to evaluate the DNA methylation patterns of cord blood mononuclear leukocytes from neonates exposed to HCA compared with healthy controls.

Materials and Methods {#s2}
=====================

Ethical Approval: Human Study Protocol and Institutional Biosafety Approvals
----------------------------------------------------------------------------

All human protocols and procedures described in this study were approved by the Institutional Review Board of Thomas Jefferson University Hospital. All experiments performed in this study were approved by the Nemours Institutional Biosafety Committee. The Institutional Review Board waived informed consent as the study was performed on discarded blood and placental tissue samples.

Study Design
------------

This is a prospective observational study to examine differential DNA methylation in mononuclear leukocytes isolated from cord blood of term neonates born to mothers with HCA compared to those without HCA. Samples of cord blood and fetal membranes were collected from term neonates (37--40 weeks of gestation). Exclusion criteria included maternal infections other than HCA, gestational diabetes, hypertension, major congenital/chromosomal anomalies, and intrauterine growth restriction.

Cord Blood Collection and Isolation of Leukocytes
-------------------------------------------------

The umbilical cord was wiped with 70% alcohol immediately after delivery and cut at the placental side of the clamp. Cord blood was collected in sterile EDTA tubes, mixed thoroughly, and evaluated for blood clots. Mononuclear leukocytes were isolated by Ficoll-Paque Plus density gradient (GE Healthcare Biosciences, Pittsburgh, PA), following the manufacturer\'s protocol and the method described previously by our group ([@B19]). Two million packed cells per vial were saved at −80°C for DNA isolation and global DNA methylation analysis.

Fetal Membrane Collection, Processing, Staining, and Diagnosis of HCA
---------------------------------------------------------------------

Fetal membrane tissues were washed with cold PBS and fixed in 10% neutral buffered formalin for 24--48 h. Membrane pieces were then processed and paraffin embedded in Histoplast LP (Thermo Fisher Scientific, Fremont, CA) following the detailed method of Gayen nee\' Betal et al. ([@B19]). Tissue samples were processed using standard operating procedures at the Nemours Histochemistry and Tissue Processing Core (Nemours, Wilmington, DE). The tissue samples were then examined by a blinded pathologist and classified either HCA (placental membranes score ≥ stage 1) or no HCA (no histological inflammatory changes in fetal membranes) ([@B20]) ([Supplemental Figure 1](#SM1){ref-type="supplementary-material"}).

DNA Isolation and Global DNA Methylation Analysis
-------------------------------------------------

Genomic DNA was isolated using QIAamp DNA Mini kit (Qiagen, Germantown, MD). DNA was quantified on a Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA), and the DNA quality was assessed by an Agilent 2200 TapeStation (Agilent Technologies, Palo Alto, CA). Analysis of genome-wide DNA methylation was performed using the Infinium HumanMethylationEPIC BeadChip array (Illumina, San Diego, CA) at the Children\'s Hospital of Philadelphia following the standard protocol provided by Illumina. In brief, 500 ng of genomic DNA was bisulfite-converted using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer\'s protocol. The Illumina iScan Reader was used to analyze the image and data from EPIC BeadChip. Data processing was performed with Illumina GenomeStudio software.

Quality Control and Statistical Approaches for DNA Methylation Analysis
-----------------------------------------------------------------------

Quality control (QC) was performed on DNA methylation data to filter out probes with missing methylation values in any samples and probes with at least 75% of samples having detected a *p* \> 0.05. 866,836 probes remained for further analysis after QC filtering. DNA methylation β-values were normalized using the SWAN normalization method in minfi package in R/Bioconductor ([@B21], [@B22]). After normalization, DNA methylation sites with maximum methylation level below 0.15 were further filtered out to remove probes with low DNA methylation levels from next step differential analysis. A general linear model approach was then used to detect the difference in methylation levels between healthy neonates and neonates born to mothers with HCA using the limma package in R/Bioconductor ([@B23]). The moderated t-statistics with empirical Bayes approach was used to estimate the differences in methylation levels between healthy neonates and those born to mothers with HCA. Top DNA methylation sites were selected by test statistics and *p*-values (with raw *p* \< 0.0001) from the two group comparisons. A Manhattan plot was used to show the selected top DNA methylation sites and their chromosome positions. A volcano plot of all DNA methylation sites was generated to show both their *p*-values and fold changes from the two group comparisons. A heatmap of methylation levels from top DNA methylation sites was generated to show the DNA methylation pattern differences between groups. All plots were generated using the program "R."

Results {#s3}
=======

Genome-wide DNA methylation was performed on mononuclear leukocytes from cord blood of 10 term neonates. Five neonates had evidence of HCA by placental histopathology (referred as "HCA Group") and five neonates had no evidence of HCA (referred as "control group").

Differential DNA Methylation
----------------------------

DNA methylation levels are represented by β-values. The β-value is the ratio of the methylated probe signal intensity to the total locus intensity. The β-values range from 0 to 1 where 0 indicates unmethylated and 1 indicates fully methylated. A boxplot ([Figure 1](#F1){ref-type="fig"}) was generated from β-values of all probe sets from the 10 samples to describe distribution of the pre-processed DNA methylation level. The interquartile range of the β-values was 0.2--0.9. Although the spread of β-values varied slightly within each group, no significant differences between groups were observed.

![The distribution of methylation level (β-values) among all of the samples from the two groups.](fped-08-00437-g0001){#F1}

Comparison of the HCA group genome-wide DNA methylation data with the control group using Illumina GenomeStudio software identified 68 differentially methylated probe-IDs with a *p* ≤ 0.0001. Of these, 44 probe-IDs were significantly hypermethylated and 24 probe-IDs were significantly hypomethylated ([Table 1](#T1){ref-type="table"}). The top 10 hyper and hypomethylated probe-IDs along with their corresponding gene names based on *p*-values are listed in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. Notable hypermethylated probe-IDs with gene names included AGR2 (Anterior Gradient Protein 2), which plays a role in asthma and mucin production ([@B24]), and OTX2 (Orthodenticle Homeobox 2), which interacts with nitric oxide ([@B25]). The top hypomethylated probe-IDs with gene names included MIER2 (Mesoderm Induction Early Response Protein 2), which regulates histone deacetylases ([@B26]), and PPP4C (Protein Phosphatase 4 Catalytic Subunit), a regulator of T-regulatory cells ([@B27]).

###### 

Differentially methylated CpGs with exposure to histological chorioamnionitis (*p* ≤ 0.0001).

  **CpG site**   **Gene symbol**                               **Methylation status**   **Chromosome**   **Strand**   **Test statistics**   **Raw *p*-value**   **Island name**             **Relation to island**   **Reference gene group**
  -------------- --------------------------------------------- ------------------------ ---------------- ------------ --------------------- ------------------- --------------------------- ------------------------ ------------------------------
  cg19448065     VGLL4; VGLL4                                  Hypermethylated genes    chr3             \+           15.189                8.54E-08                                        OpenSea                  Body; Body
  cg00995577     AGR2                                                                   chr7             \+           10.897                1.53E-06                                        OpenSea                  TSS1500
  cg12363975     AGAP1; AGAP1; AGAP1                                                    chr2             \+           10.709                1.78E-06                                        OpenSea                  Body; Body; Body
  cg26386257                                                                            chr7             \+           10.633                1.89E-06                                        OpenSea                  
  cg09304034     SMIM15;CTC-436P18.1                                                    chr5             --           9.534                 4.75E-06            chr5:60457840-60458654      N_Shore                  5′UTR;TSS1500
  cg08049519                                                                            chr15            --           9.363                 5.53E-06            chr15:81410715-81411067     S_Shore                  
  cg16380389                                                                            chr16            --           9.043                 7.39E-06            chr16:90069762-90070883     Island                   
  cg04381379     CELF4; CELF4; CELF4;CELF4                                              chr18            \+           8.385                 1.38E-05                                        OpenSea                  Body; Body; Body; Body
  cg27344140                                                                            chr3             \+           8.329                 1.45E-05                                        OpenSea                  
  cg08258922                                                                            chr14            --           8.129                 1.77E-05            chr14:103745232-103746271   Island                   
  cg02086467     OTX2                                                                   chr14            --           7.855                 2.34E-05            chr14:57274607-57276840     Island                   5′UTR
  cg18196614     MCM8-AS1                                                               chr20            \+           7.710                 2.72E-05            chr20:5986399-5987297       N_Shelf                  Body
  cg04040779     NUP160                                                                 chr11            --           7.439                 3.62E-05                                        OpenSea                  Body
  cg14508517     NAALADL2                                                               chr3             --           7.340                 4.03E-05                                        OpenSea                  Body
  cg15057251     MAPRE2; MAPRE2; MAPRE2; MAPRE2                                         chr18            --           7.306                 4.18E-05            chr18:32621215-32621689     Island                   TSS200; 5′UTR; TSS200; Body
  cg06977182     SEMA6A; SEMA6A                                                         chr5             --           7.296                 4.22E-05                                        OpenSea                  Body; Body
  cg04423025     PRCP; PRCP                                                             chr11            \+           7.292                 4.24E-05                                        OpenSea                  Body; Body
  cg18426912     NDUFAF5; NDUFAF5; NDUFAF5                                              chr20            --           7.190                 4.74E-05            chr20:13765166-13765909     S_Shelf                  Body; Body; Body
  cg07417772     GOLIM4; GOLIM4                                                         chr3             \+           7.155                 4.93E-05                                        OpenSea                  Body; Body
  cg21147013     LOC102467224                                                           chr5             \+           7.126                 5.09E-05                                        OpenSea                  Body
  cg10176510     NDUFAF4                                                                chr6             --           7.124                 5.10E-05                                        OpenSea                  3′UTR
  cg18159802                                                                            chr11            \+           7.117                 5.14E-05                                        OpenSea                  
  cg07891737     MIR519D; MIR517A                                                       chr19            \+           7.113                 5.16E-05                                        OpenSea                  TSS1500; Body
  cg16510851                                                                            chr3             \+           7.109                 5.18E-05                                        OpenSea                  
  cg05574878     MIR1912; HTR2C                                                         chrX             --           6.959                 6.13E-05                                        OpenSea                  TSS1500; 5′UTR
  cg07277182     FANCM; FANCM                                                           chr14            \+           6.958                 6.13E-05                                        OpenSea                  Body; Body
  cg03508395                                                                            chr14            \+           6.947                 6.21E-05            chr14:104927441-104928653   S_Shore                  
  cg00080312     SACM1L                                                                 chr3             --           6.932                 6.32E-05            chr3:45730615-45731294      N_Shore                  TSS1500
  cg16077353     STXBP5-AS1                                                             chr6             --           6.904                 6.52E-05                                        OpenSea                  Body
  cg26548811     LOC101929239; PACRG; PACRG; PACRG                                      chr6             --           6.903                 6.52E-05                                        OpenSea                  Body; Body; Body; Body
  cg12540696     FMN2; FMN2                                                             chr1             --           6.889                 6.63E-05                                        OpenSea                  Body; Body
  cg14541152     SCAMP5                                                                 chr15            --           6.876                 6.73E-05            chr15:75315855-75316178     N_Shelf                  3′UTR
  cg22184818     TTC29; TTC29                                                           chr4             --           6.873                 6.75E-05                                        OpenSea                  Body; Body
  cg06028808                                                                            chr11            \+           6.840                 7.01E-05                                        OpenSea                  
  cg00558645                                                                            chr1             \+           6.814                 7.22E-05                                        OpenSea                  
  cg17130789     SLC11A1                                                                chr2             --           6.806                 7.29E-05            chr2:219255949-219256210    Island                   Body
  cg07480541     LRCH2; LRCH2                                                           chrX             \+           6.706                 8.17E-05                                        OpenSea                  Body; Body
  cg02021337     KLHL24                                                                 chr3             \+           6.686                 8.36E-05                                        OpenSea                  3′UTR
  cg05063703                                                                            chr9             \+           6.673                 8.49E-05                                        OpenSea                  
  cg18189005     CACNA1A; CACNA1A; CACNA1A; CACNA1A; CACNA1A                            chr19            \+           6.669                 8.53E-05                                        OpenSea                  Body; Body; Body; Body; Body
  cg22396161     ATP7A                                                                  chrX             --           6.667                 8.55E-05                                        OpenSea                  3′UTR
  cg17341671                                                                            chr1             \+           6.555                 9.73E-05                                        OpenSea                  
  cg03514545     SYT6                                                                   chr1             \+           6.551                 9.79E-05            chr1:114696886-114697185    N_Shore                  TSS1500
  cg26013396     SGPP1                                                                  chr14            --           6.547                 9.83E-05            chr14:64194241-64195049     N_Shelf                  Body
  cg02417264     RAMP3                                         Hypomethylated genes     chr7             \+           −6.570                9.56E-05            chr7:45197181-45197807      Island                   Body
  cg12693181                                                                            chr11            --           −6.613                9.10E-05            chr11:18067716-18067928     N_Shelf                  
  cg19315263     ZNF471                                                                 chr19            \+           −6.615                9.08E-05            chr19:57018743-57019506     S_Shore                  5′UTR
  cg12313868                                                                            chr11            --           −6.718                8.06E-05                                        OpenSea                  
  cg15343100     CCDC68; CCDC68                                                         chr18            --           −6.735                7.90E-05            chr18:52626517-52626849     N_Shore                  TSS1500; 5′UTR
  cg16408982                                                                            chr14            \+           −6.805                7.30E-05            chr14:103522988-103524431   S_Shelf                  
  cg26933865     PPP4C                                                                  chr16            \+           −6.904                6.52E-05            chr16:30087236-30087842     N_Shore                  TSS1500
  cg12743398     SULT1A2                                                                chr16            \+           −6.953                6.17E-05            chr16:28611946-28612388     N_Shelf                  TSS1500
  cg18901644     GPR78                                                                  chr4             --           −7.030                5.66E-05            chr4:8582036-8583364        Island                   TSS200
  cg01293188                                                                            chr4             \+           −7.117                5.14E-05                                        OpenSea                  
  cg19870898                                                                            chr14            --           −7.124                5.10E-05            chr14:103673773-103674343   S_Shelf                  
  cg24376295                                                                            chr3             --           −7.219                4.59E-05            chr3:188665275-188665552    Island                   
  cg25137968     HIST2H2BA                                                              chr1             \+           −7.252                4.43E-05            chr1:120905971-120906396    N_Shore                  TSS1500
  cg05030450     ODZ2                                                                   chr5             \+           −7.327                4.08E-05                                        OpenSea                  Body
  cg10051200     CPEB4; CPEB4; CPEB4; CPEB4; CPEB4                                      chr5             --           −7.441                3.61E-05                                        OpenSea                  Body; Body; Body; Body; Body
  cg03568094                                                                            chr20            \+           −7.534                3.27E-05            chr20:61196870-61197072     N_Shelf                  
  cg14887613     MIER2                                                                  chr19            \+           −7.674                2.82E-05            chr19:345260-345590         Island                   TSS1500
  cg18584280                                                                            chr15            \+           −7.736                2.65E-05                                        OpenSea                  
  cg11503661                                                                            chr2             \+           −7.775                2.54E-05            chr2:242788781-242791121    Island                   
  cg24239266     OR13C2                                                                 chr9             \+           −8.256                1.56E-05                                        OpenSea                  1stExon
  cg25036067                                                                            chr3             \+           −9.936                3.36E-06                                        OpenSea                  
  cg14469826     ABCC8                                                                  chr11            \+           −10.509               2.09E-06            chr11:17497463-17498626     S_Shore                  TSS1500
  cg01097406                                                                            chr16            --           −15.204               8.46E-08                                        OpenSea                  
  cg27450744                                                                            chr8             \+           −39.924               1.43E-11            chr8:143645072-143645673    Island                   

###### 

Top 10 hypermethylated CpGs with exposure to histological chorioamnionitis (*p* ≤ 0.0001).

  **CpG site**   **Gene symbol**        **Gene name**                                                                     **Chromosome**   **Strand**   **Test statistics**   **Raw *p*-value**   **Relation to Island**   **Gene location of first annotated transcript**
  -------------- ---------------------- --------------------------------------------------------------------------------- ---------------- ------------ --------------------- ------------------- ------------------------ -------------------------------------------------
  cg19448065     VGLL4                  Vestigial Like Family Member 4                                                    chr3             \+           15.189                8.54E-08            OpenSea                  Body
  cg00995577     AGR2                   Anterior Gradient 2, Protein Disulphide Isomerase Family Member                   chr7             \+           10.897                1.53E-06            OpenSea                  TSS1500
  cg12363975     AGAP1                  ArfGAP With GTPase Domain, Ankyrin Repeat And PH Domain 1                         chr2             \+           10.709                1.78E-06            OpenSea                  Body
  cg09304034     SMIM15; CTC-436P18.1   SMIM15 Antisense RNA 1 (aka Small Integral Membrane Protein 15 Antisense RNA 1)   chr5             --           9.534                 4.75E-06            N_Shore                  5′UTR; TSS1500
  cg04381379     CELF4                  CUGBP Elav-Like Family Member 4                                                   chr18            \+           8.385                 1.38E-05            OpenSea                  Body
  cg02086467     OTX2                   Orthodenticle Homeobox 2                                                          chr14            --           7.855                 2.34E-05            Island                   5′UTR
  cg18196614     MCM8-AS1               MCM8 Antisense RNA1                                                               chr20            \+           7.710                 2.72E-05            N_Shelf                  Body
  cg04040779     NUP160                 Nucleoporin 160                                                                   chr11            --           7.439                 3.62E-05            OpenSea                  Body
  cg14508517     NAALADL2               N-Acetylated Alpha-Linked Acidic Dipeptidase Like 2                               chr3             --           7.340                 4.03E-05            OpenSea                  Body
  cg15057251     MAPRE2                 Microtubule Associated Protein RP/EB Family Member 2                              chr18            --           7.306                 4.18E-05            Island                   TSS200

###### 

Top 10 hypomethylated CpGs with exposure to histological chorioamnionitis (*p* ≤ 0.0001).

  **CpG site**   **Gene symbol**   **Gene name**                                                                     **Chromosome**   **Strand**   **Test statistics**   **Raw *p*-value**   **Relation to island**   **Gene location of first annotated transcript**
  -------------- ----------------- --------------------------------------------------------------------------------- ---------------- ------------ --------------------- ------------------- ------------------------ -------------------------------------------------
  cg14469826     ABCC8             ATP binding cassette subfamily C member 8                                         chr11            \+           −10.509               2.09E-06            S_Shore                  TSS1500
  cg24239266     OR13C2            Olfactory receptor family 13 subfamily C member 2                                 chr9             \+           −8.256                1.56E-05            OpenSea                  1stExon
  cg14887613     MIER2             MIER Family Member 2 (aka Mesoderm Induction Early Response 1, Family Member 2)   chr19            \+           −7.674                2.82E-05            Island                   TSS1500
  cg10051200     CPEB4             Cytoplasmic Polyadenylation Element Binding Protein 4                             chr5             --           −7.441                3.61E-05            OpenSea                  Body
  cg05030450     ODZ2              Teneurin Transmembrane Protein 2                                                  chr5             \+           −7.327                4.08E-05            OpenSea                  Body
  cg25137968     HIST2H2BA         Histone Cluster 2 H2B Family Member A (Pseudogene)                                chr1             \+           −7.252                4.43E-05            N_Shore                  TSS1500
  cg18901644     GPR78             G Protein-Coupled Receptor 78                                                     chr4             --           −7.030                5.66E-05            Island                   TSS200
  cg12743398     SULT1A2           Sulfotransferase Family 1A Member 2                                               chr16            \+           −6.953                6.17E-05            N_Shelf                  TSS1500
  cg26933865     PPP4C             Protein Phosphatase 4 Catalytic Subunit                                           chr16            \+           −6.904                6.52E-05            N_Shore                  TSS1500
  cg15343100     CCDC68            Coiled-Coil Domain Containing 68                                                  chr18            --           −6.735                7.90E-05            N_Shore                  TSS1500

A Manhattan plot ([Figure 2](#F2){ref-type="fig"}) shows the distribution of possible differentially methylated CpG sites identified across chromosomes. Genome-wide significance threshold of *p* ≤ 0.0001 was used as a cut off (red line). The top candidates in pairwise comparison were selected by test statistics and *p*-values for comparison. The black dotted line indicates a significance threshold of *p* ≤ 10^−7^. Three probe sets including two non-annotated probes (cg27450744, cg01097406) and VGLL4 (cg19448065) remained significant at a threshold of *p* ≤ 10^−7^. The differentially methylated CpG sites are depicted in a volcano plot ([Figure 3](#F3){ref-type="fig"}). A volcano plot is a scatter plot of significance, the negative log of the *p*-value vs. the log of fold change.

![The distribution of differentially methylated CpG sites identified across chromosomes. The x-axis represents the chromosomal location of the CpG probes. The y-axis represents differential methylation as the negative log of the *p*-value of their association. Genome-wide significance threshold of *p* ≤ 0.0001 is used as a cut off (horizontal red line). The black dotted line indicates a significance threshold of *p* ≤ 10^−7^.](fped-08-00437-g0002){#F2}

![The differentially methylated CpG sites between the HCA and control groups. The x-axis shows difference in mean percent of DNA methylation and the y-axis shows the significance of differential methylation of each probe, represented as the negative log of the *p*-value. The red and green line indicate genome-wide significance thresholds of *p* ≤ 0.0001 and *p* ≤ 10^−7^, respectively.](fped-08-00437-g0003){#F3}

Cluster Analysis -- Heatmap
---------------------------

Cluster analysis was performed on the 68 differentially methylated loci for the two sample groups using the hierarchical clustering method. A heatmap of the methylation levels for the 68 DNA methylation loci illustrates the differences between the two groups ([Figure 4](#F4){ref-type="fig"}). The hypermethylated loci are depicted in green, and the hypomethylated loci are depicted in red. Each column in the heatmap represents a sample.

![The 68 differentially methylated probe sets (*p* ≤ 0.0001) in the individual HCA samples (right) compared to control samples (left). The green and red colors indicate hyper-methylated and hypo-methylated loci, respectively.](fped-08-00437-g0004){#F4}

Differential DNA Methylation Related to Immune Response
-------------------------------------------------------

Eleven genes related to immune response and regulation of inflammatory pathways were identified ([Table 4](#T4){ref-type="table"}). Seven genes were hypermethylated and 4 genes were hypomethylated. The hypermethylated genes have roles in asthma (VGLL4, AGR2) ([@B24], [@B28]), neurologic development (AGAP1, OTX2) ([@B29], [@B30]), and immune regulation (SCAMP5, SLC11A1) ([@B31], [@B32]). The hypomethylated genes have roles in immune regulation (PPP4C) ([@B27]), transcription regulation (MIER2) ([@B26]), and inflammation (ABCC8) ([@B33]).

###### 

Key genes related to immune response with exposure to histological chorioamnionitis (*p* ≤ 0.0001).

  **CpG site**   **Gene symbol**       **Chromosome**   **Strand**   **Test statistics**   **Methylation status**   **Raw *p*-values**   **Relation to Island**   **Gene location/Reference gene group**
  -------------- --------------------- ---------------- ------------ --------------------- ------------------------ -------------------- ------------------------ ----------------------------------------
  cg19448065     VGLL4; VGLL4          chr3             \+           15.189                Hyper-methylated genes   8.54E-08             OpenSea                  Body; Body
  cg00995577     AGR2                  chr7             \+           10.897                                         1.53E-06             OpenSea                  TSS1500
  cg12363975     AGAP1; AGAP1; AGAP1   chr2             \+           10.709                                         1.78E-06             OpenSea                  Body; Body; Body
  cg02086467     OTX2                  chr14            --           7.855                                          2.34E-05             Island                   5′UTR
  cg14541152     SCAMP5                chr15            --           6.876                                          6.73E-05             N_Shelf                  3′UTR
  cg17130789     SLC11A1               chr2             --           6.806                                          7.29E-05             Island                   Body
  cg26933865     PPP4C                 chr16            \+           −6.904                Hypo-methylated genes    6.52E-05             N_Shore                  TSS1500
  cg14887613     MIER2                 chr19            \+           −7.674                                         2.82E-05             Island                   TSS1500
  cg14469826     ABCC8                 chr11            \+           −10.509                                        2.09E-06             S_Shore                  TSS1500

Ingenuity Pathway Analysis
--------------------------

Ingenuity Pathway Analysis (IPA) software (Qiagen Inc., Germantown, MD) was used to perform pathway analysis by loading 448 probe sets that were found to be differentially methylated with exposure to HCA for a *p* ≤ 0.001. A total of 76 diseases and functions were altered with exposure to HCA. Selected key diseases and functions altered with HCA are listed in [Table 5](#T5){ref-type="table"}. The modification of functions with HCA included genes related to nervous system development and function, inflammatory response and disease, cellular movement, death and survival, hematological system development and function, and respiratory disease, development and function. IPA identified 224 canonical pathways that were modified with exposure to HCA. Selected key pathways important in immune regulation and inflammatory responses are shown in [Table 6](#T6){ref-type="table"}.

###### 

Diseases and functions modified with exposure to histological chorioamnionitis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Modified diseases and functions**             ***p*-value**          **Number of molecules involved**   **Molecules involved**
  ----------------------------------------------- ---------------------- ---------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nervous system development and function         3.08E-04 to 2.03E-02   30                                 LINGO2,GRM3,MYT1L,SPTBN1,PTN,NLGN1,IL1R1,PIK3CA,HMGB1,PDE11A,CNTNAP2,HS6ST1,ELMO1,\
                                                                                                            HSF1,LRRC4C,SCAMP5,SHANK1,ALK,OTX2,TENM2,RMST,IRX6,RAB21,NMU,ATP7A,KLF7,CCND1,PRKAA2,ARHGAP32,LRRK2

  Inflammatory response                           3.09E-04 to 1.58E-02   10                                 HMGB1,IL1R1,ATG5,PDE11A,CCND1,TUBB1,ALK,SOS1,TRNT1,HSF1

  Inflammatory disease                            3.82E-04 to 1.58E-02   8                                  IL1R1,HMGB1,NAALADL2,PDE11A,COL28A1,CSMD1,CACNA2D3,TUBB1

  Cell death and survival                         1.01E-03 to 2.03E-02   17                                 SF3B1,TBP,ATG5,TUB,ABCC1,OTX2,CD70,GALNT3,HMGB1,IL1R1,CCND1,PRKAA2,MEIS1,MYSM1,LRRK2,ELMO1,HSF1

  Cellular movement                               1.01E-03 to 1.91E-02   16                                 LDLRAP1,RECK,ALK,SOS1,IGF2R,SYT7,HAS2,HMGB1,PIK3CA,IL1R1,CCND1,PRKAA2,IL19,RAMP3,ELMO1,ETV6

  Hematological system development and function   1.01E-03 to 2.03E-02   8                                  NMU,HMGB1,PIK3CA,CCND1,TUBB1,TMOD3,TSPAN33,SOS1

  Immune cell trafficking                         1.01E-03 to 2.03E-02   4                                  HMGB1,PIK3CA,CCND1,SOS1

  Neurological disease                            1.05E-03 to 2.03E-02   32                                 TBP,SF3B1,TUBB1,CSNK1G2,GRM3,MYT1L,RPL5,KANSL1,PIK3CA,IL1R1,KIAA0556,CNTNAP2,HS6ST1,SACS,ELMO1,\
                                                                                                            HSF1,BRAT1,RECK,TAF2,ALK,ACO2,SLC25A16,NALCN,ABCC1,OTX2,TENM2,NAV3,ATP7A,KLF7,CCND1,FAM174B,LRRK2

  Cellular development                            1.34E-03 to 1.74E-02   43                                 ATG5,FGF19,DOCK4,ELF2,LINGO2,GRM3,MYT1L,SPTBN1,PTN,HAS2,NLGN1,IL1R1,PIK3CA,HMGB1,BATF2,CNTNAP2,\
                                                                                                            HS6ST1,TSPAN33,ELMO1,HSF1,LRRC4C,LDLRAP1,RECK,TNK1,SHANK1,ALK,MAGED1,OTX2,SOS1,CD70,GALNT3,RMST,I\
                                                                                                            RX6,RAB21,XPO1,ATP7A,KLF7,CCND1,PRKAA2,ARHGAP32,LRRK2,ETV6,LTBP1

  Cellular growth and proliferation               1.34E-03 to 2.03E-02   51                                 ATG5,FGF19,ELF2,GRM3,IFT52,HMGB1,CNTNAP2,HS6ST1,TSPAN33,HSF1,LRRC4C,LDLRAP1,RECK,ALK,CD70,GALNT3,\
                                                                                                            IRX6,RAB21,XPO1,ATP7A,CCND1,RASGRF2,MEIS1,LRRK2,DOCK4,LINGO2,AGR2,MYT1L,SPTBN1,PTN,HAS2,NLGN1,IL1R1,\
                                                                                                            PIK3CA,BATF2,HDAC4,ELMO1,TNK1,SHANK1,AICDA,MAGED1,ABCC1,OTX2,SOS1,RMST,KLF7,AQP2,PRKAA2,ARHGAP32,ETV6,LTBP1

  Respiratory disease                             2.1E-03 to 2.03E-02    18                                 SF3B1,CSMD1,TUBB1,AICDA,ALK,OTX2,GRM3,NAV3,MYF5,RPL5,HMGB1,IL1R1,PIK3CA,CCND1,CNTNAP2,LRRK2,MEGF11,HSF1

  Immunological disease                           2.17E-03 to 2E-02      40                                 SF3B1,TBP,ATG5,TUBB1,ELF2,CSNK1G2,ZMIZ1,GRM3,SPTBN1,KLHL24,RPL5,HMGB1, PIK3CA,PDE11A,IL1R1,CNTNAP2,HDAC4,ELMO1,TRNT1,LRRC1,FAM189A1,TNK1,SHANK1, AICDA,ALK,NALCN,ABCC1,TENM2,CD70,OTX2,SOS1,NAV3,EYS,XPO1,CCND1,EIF2A, TPST2,LRRK2,ETV6,LTBP1

  DNA replication, recombination, and repair      2.18E-03 to 1.58E-02   8                                  SNX13,XPO1,TBP,PIK3CA,HMGB1,PDE11A,PRKAA2,ABCC1

  Cellular function and maintenance               2.78E-03 to 1.75E-02   43                                 DYM,VPS37D,ATG5,TUB,DOCK4,GMNC,BHLHA15,SPTBN1,KLHL24,IFT52,HAS2,PTN,NLGN1,PIK3CA,HMGB1,IL1R1,WDR41,\
                                                                                                            TESK2,CNTNAP2,TMOD3,NUDCD3,HDAC4,ELMO1,HSF1,LRRC4C,BRAT1,ABCC1,NUP160,UBASH3B,NAV3,CLIP3,RAB21,XPO1,\
                                                                                                            ATP7A,KLF7,CCND1,EIF2A,RAB32,PRKAA2,ARHGAP32,KIF18B,LRRK2,KDM4A

  Respiratory system development and function     2.78E-03 to 2.03E-02   4                                  MYF5,HMGB1,OTX2,HSF1

  Cell cycle                                      2.82E-03 to 2.03E-02   27                                 ATG5,CDK14,TUBB1,MYF5,HAS2,PTN,HMGB1,PIK3CA,SACM1L,TMOD3,NUDCD3,HDAC4,HSF1,RECK,CENPH,ALK,ANKS1A,\
                                                                                                            MAGED1,CD70,XPO1,CCND1,MEIS1,ARHGAP32,MCIDAS,KIF18B,LRRK2,LTBP1

  Cell-to-cell signaling and interaction          3.76E-03 to 2.03E-02   17                                 ATG5,FGF19,PTS,ALK,MAGED1,IGF2R,GRM3,RAB21,HAS2,NMU,NLGN1,HMGB1,IL1R1,PDE11A,PIK3CA,CNTNAP2,LRRK2

  Cell-mediated immune response                   1.02E-02 to 1.02E-02   1                                  PIK3CA

  Gene expression                                 1.02E-02 to 2.03E-02   2                                  TBP,HMGB1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Canonical pathways in Ingenuity Pathway Analysis associated with exposure to histological chorioamnionitis.

  **Ingenuity canonical pathways**                                       **--log(*p*-value)**   **Molecules involved in pathways**           **Importance**
  ---------------------------------------------------------------------- ---------------------- -------------------------------------------- --------------------------
  CREB signaling in neurons                                              2.23                   TBP,PIK3CA,GRID1,CACNA2D3,CACNG3,SOS1,GRM3   Neuronal protection
  FcγRIIB signaling in B lymphocytes                                     2.06                   PIK3CA,CACNA2D3,CACNG3,SOS1                  Apoptosis, autoimmunity
  Cell cycle: G1/S checkpoint regulation                                 1.54                   RPL5,CCND1,HDAC4                             Cell cycle regulation
  HGF signaling                                                          1.53                   PIK3CA,CCND1,ELF2,SOS1                       T-cell related
  Tetrahydrobiopterin biosynthesis I                                     1.52                   PTS                                          Alters neurotransmitters
  Tetrahydrobiopterin biosynthesis II                                    1.52                   PTS                                          Alters neurotransmitters
  GM-CSF signaling                                                       1.41                   PIK3CA,CCND1,SOS1                            Immune response
  3-phosphoinositide biosynthesis                                        1.31                   SGPP1,PIK3CA,UBLCP1,PPP4C,SACM1L             Cell cycle regulation
  Glucocorticoid receptor signaling                                      1.24                   GTF2H3,TBP,HMGB1,PIK3CA,TAF2,PRKAA2,SOS1     Inflammation/Stress
  IL-7 signaling pathway                                                 1.24                   PIK3CA,CCND1,SOS1                            Immune response
  FGF signaling                                                          1.18                   PIK3CA,FGF19,SOS1                            Cell proliferation
  3-phosphoinositide degradation                                         1.15                   SGPP1,UBLCP1,PPP4C,SACM1L                    Cell cycle regulation
  Role of NFAT in cardiac hypertrophy                                    1.15                   PIK3CA,CACNA2D3,CACNG3,HDAC4,SOS1            Immune modulation
  PKCθ signaling in T lymphocytes                                        1.14                   PIK3CA,CACNA2D3,CACNG3,SOS1                  Immune response
  G beta gamma signaling                                                 0.955                  CACNA2D3,CACNG3,SOS1                         Inflammation
  Melatonin degradation I                                                0.953                  SULT1A2,CYP2S1                               CNS
  Glutamate receptor signaling                                           0.953                  GRID1,GRM3                                   CNS
  Role of NFAT in regulation of the immune response                      0.943                  XPO1,PIK3CA,CSNK1G2,SOS1                     Immune response
  CNTF signaling                                                         0.904                  PIK3CA,SOS1                                  CNS
  Superpathway of melatonin degradation                                  0.892                  SULT1A2,CYP2S1                               CNS
  PI3K/AKT signaling                                                     0.883                  PIK3CA,CCND1,SOS1                            Cell cycle regulation
  IL-2 signaling                                                         0.858                  PIK3CA,SOS1                                  Immune response
  IL-6 Signaling                                                         0.846                  PIK3CA,IL1R1,SOS1                            Immune response
  HMGB1 signaling                                                        0.825                  HMGB1,PIK3CA,IL1R1                           Inflammation
  LPS/IL-1 mediated inhibition of RXR function                           0.782                  XPO1,IL1R1,SULT1A2,HS6ST1                    Inflammation
  GADD45 signaling                                                       0.752                  CCND1                                        Cell cycle regulation
  GDNF family ligand-receptor interactions                               0.741                  PIK3CA,SOS1                                  CNS
  Neurotrophin/TRK signaling                                             0.732                  PIK3CA,SOS1                                  CNS
  IL-17A signaling in airway cells                                       0.724                  PIK3CA,IL19                                  Inflammation
  Cyclins and cell cycle regulation                                      0.715                  CCND1,HDAC4                                  Cell cycle regulation
  IL-3 signaling                                                         0.683                  PIK3CA,SOS1                                  Immune response
  FLT3 signaling in hematopoietic progenitor cells                       0.683                  PIK3CA,SOS1                                  Immune response
  IL-17 signaling                                                        0.668                  PIK3CA,IL19                                  Inflammation
  PPAR signaling                                                         0.618                  IL1R1,SOS1                                   Transcription factor
  PPARα/RXRα activation                                                  0.61                   IL1R1,PRKAA2,SOS1                            Transcription factor
  Dopamine degradation                                                   0.577                  SULT1A2                                      CNS
  T cell receptor signaling                                              0.521                  PIK3CA,SOS1                                  Immune response
  p53 signaling                                                          0.505                  PIK3CA,CCND1                                 Cell proliferation
  Serotonin receptor signaling                                           0.456                  PTS                                          CNS
  Serotonin degradation                                                  0.317                  SULT1A2                                      CNS
  IL-10 signaling                                                        0.295                  IL1R1                                        Inflammation
  Wnt/β-catenin signaling                                                0.288                  CCND1,CSNK1G2                                Cell Signaling
  Dopamine receptor signaling                                            0.266                  PTS                                          CNS
  Regulation of IL-2 expression in activated and anergic T lymphocytes   0.255                  SOS1                                         Immune response
  B cell receptor signaling                                              0.242                  PIK3CA,SOS1                                  Immune response
  IL-8 signaling                                                         0.225                  PIK3CA,CCND1                                 Inflammation
  IL-1 signaling                                                         0.214                  IL1R1                                        Inflammation
  CTLA4 Signaling in Cytotoxic T Lymphocytes                             0.198                  PIK3CA                                       Immune response

IPA identified 15 networks, of which network 2 (cellular growth and proliferation, cellular development, connective tissue development and function) and network 13 (cellular movement, hematological system development and function, immune cell trafficking) are closely related to the focus of this study.

Discussion {#s4}
==========

Exposure to HCA is associated with an increased risk of medical problems later in life including cerebral palsy, developmental delay, asthma, and allergic disorders ([@B6]--[@B13]). Although the mechanism of this increased risk is not yet known, alteration in gene expression secondary to differential DNA methylation may contribute to this increased risk. To our knowledge, this is the first study to report differential DNA methylation in human cord blood mononuclear leukocytes in term neonates exposed to HCA. Our data suggest that HCA altered the methylation status of genes involved in inflammation, immune regulation, respiratory development, and neurologic development in cord blood mononuclear leukocytes from term neonates.

Infants born to mothers with HCA are at increased risk for asthma but the exact mechanism is unknown ([@B6], [@B7], [@B11], [@B12]). Our results show that exposure to HCA was associated with differential methylation of several genes involved in signaling pathways related to the lung development, lung inflammation, and asthma. Vestigial Like Family Member 4 (VGLL4) is a gene related to Wnt/β-catenin signaling pathway regulation, cell cycle regulation, and immune regulation via T-cell mediated tumor regression ([@B28], [@B34], [@B35]). The Wnt/β-catenin signaling pathway plays a pivotal role in lung development, lung injury, and repair ([@B28]). Aberrant expression of Wnt/β-catenin signaling can lead to asthmatic airway remodeling with hyperplasia of airway smooth muscle cells, goblet cell metaplasia, and extracellular matrix deposition ([@B28]). Down-regulation of VGLL4 due to hypermethylation after exposure to HCA could lead to dysregulation of Wnt/β-catenin signaling, abnormal lung development, and an increased risk for asthma.

Cyclin D-1 gene (CCND1), another regulator of the Wnt/β-catenin signaling pathway, is differentially methylated after exposure to HCA and associated with airway remodeling and smooth muscle proliferation in asthma ([@B36], [@B37]). Mutation in the ATP Binding Cassette Subfamily C Member 8 (ABCC8) gene is associated with pulmonary arterial hypertension ([@B38]). Receptor Activity-Modifying Protein 3 (RAMP3), the top hypomethylated gene with exposure to HCA, plays a role in human lung development ([@B39]). An additional top hypermethylated gene is Anterior Gradient 2 (AGR2), a protein disulfide isomerase family member known to be involved in asthma and allergen-induced mucin production ([@B24]).

Previous studies have also shown that HCA is associated with neurodevelopmental impairment and cerebral palsy ([@B8]--[@B10], [@B13]). Several genes involved in nervous system development and function, neurological diseases, and neurological pathways were found to be differentially methylated in cord blood mononuclear leukocytes after exposure to HCA. Hypermethylated genes involved in neurological disorders include AGAP1, CACNA1A, and OTX2. AGAP1 is known to be involved in dopamine regulation and has been shown to increase endocytic recycling of M5 muscarinic receptors involved in dopamine release in the midbrain ([@B29]). Recent work by Pacault et al. showed that deletion of AGAP1 is reported in a patient with autism ([@B40]). Genetic variation in the CACNA1A gene is associated with cerebral palsy ([@B41]). OTX2 mutations are associated with severe ocular phenotypes, seizures, and developmental delay ([@B30]).

Examples of hypomethylated genes in our study include ABCC8, MIER2, and PPP4C. ABCC8 has been shown to be associated with inflammation regulation in the nervous system in autoimmune encephalomyelitis ([@B33]). MIER2 is involved in recruitment of histone deacetylase complexes ([@B26]). PPP4C plays a key role in cortical neurodevelopment by ensuring symmetric division of early cortical cells ([@B42]). Absence of PPP4C has been shown to result in early asymmetric division and premature neurogenesis. Hypomethylation of PPP4C may result in abnormal cortical development, increasing the risk of neurodevelopmental disorders. PPP4C has also been shown to be involved in immune regulation through proliferation and expansion of regulatory T cells and subsequent adaptive immunity ([@B27]). We speculate that the fetal systemic inflammatory response from HCA leads to changes in methylation pattern in leukocytes. The systemic inflammatory response outside the fetal brain can induce neuroinflammation and neuronal injury ([@B43], [@B44]). The inflammatory response in fetal brain due to HCA may change the DNA methylation pattern in nervous system cells.

We report differential DNA methylation in genes involved in lung development, neurodevelopment, immune regulation, and inflammation after exposure to HCA. Changes in DNA methylation may result in differential gene expression and alter these processes throughout life, being a potential mechanism for the increased risk of disorders seen with exposure to HCA. Our hierarchical clustering method analysis showed extremely consistent results across the samples from each group suggesting high reliability of the differential methylation patterns that we found. Furthermore, IPA identified diseases and functions that were consistent with the known associations of HCA, including modification of nervous system development and function, inflammatory response and disease, as well as respiratory disease, development, and function.

Our study has multiple strengths. This is the first study reporting differential DNA methylation of cord blood mononuclear leukocytes in term neonates born to mothers with HCA. Genome-wide DNA methylation was performed on the mononuclear leukocytes rather than whole blood. We chose umbilical cord blood which allowed us to obtain a significant volume of blood with no invasive risk to the neonate. We also recognize several limitations in our study. The sample size of 10 neonates is small, although similar sample sizes have been used in prior studies of differential DNA methylation ([@B45]). There is a chance of finding differential gene expression when comparing such a high number of genes but that was mitigated by using a very stringent *p*-value. Another weakness of the study is a lack a validation cohort. A larger study to confirm our finding is needed.

Conclusions {#s5}
===========

Exposure to HCA results in differential DNA methylation of cord blood mononuclear leukocytes in term neonates. This differential DNA methylation was present in genes involved in immune modulation, inflammation, lung development, and nervous system development. Future studies are needed to further validate these results in a larger group of neonates and by examining functional differences related to these genes. Our data may lead to an improved understanding of the genes and pathways involved in exposure to HCA. Identifying and understanding the role of novel candidate genes can lead to the development of prognostic biomarkers and therapies to mitigate the long-term consequences of abnormal DNA methylation induced by HCA.
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